Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen, Geneart to Sell Synthetic Genes for Protein Production

NEW YORK (GenomeWeb News) – Qiagen and German gene synthesis company Geneart announced today that they are collaborating to commercialize a set of plasmids containing synthetic genes representing the entire human genome.
 
The QIAgenes plasmids will allow researchers to produce large quantities of some 35,000 human proteins. The product stems from a joint research and development project between Qiagen and Geneart, wherein Geneart contributed plasmid and gene synthesis technology and Qiagen supplied automated protein purification technology.
 
According to Qiagen, validation experiments done on 100 proteins indicate that the QIAgenes have success rates exceeding 90 percent and yield 50 times more protein than conventional methods, resulting from optimized synthetic genes and purification methods.
 
“In the past, researchers faced a multiple bottleneck situation when producing protein in sufficient quantity and quality for their research,” Kai te Kaat, Qiagen's global business director for proteins, said in a statement. “With the new QIAgenes product portfolio … our customers can now access the human proteome with a simple mouse click and significantly increase their successes expressing and purifying their protein of choice.”

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more